Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis
Key facts
- Who runs it
- Santersus AG
- Where
- Germany, Switzerland, and United Kingdom9 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 73 people, planned
- Started
- 1 Jul 2025
- Expected to end
- 28 May 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- NucleoCapture device
- Record updated
- 29 November 2024
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Adult patients aged 18-75
- Proven or suspected respiratory sepsis aetiology
- Acute respiratory failure currently requiring invasive mechanical ventilation for not more than 48 hours duration
- Horowitz Index for Lung Function (Pa02/Fi02 Ratio) ≤200mmHg or ≤26.6kPa
- Sequential organ failure assessment score (SOFA) ≥4 and ≤ 14
- Have provided written informed consent or consent is given by the patient's legally designated representative or an independent physician (if possible, according to local law)
Who cannot take part
- The use of other non-routine extracorporeal sepsis treatments such as very high flux renal replacement therapy (>60ml/kg/h total exchange), use of high cut off filters or other non-routine extracorporeal treatment columns such as Cytosorb, Toramyxcin, etc)
- Long term oxygen therapy or home oxygen use
- Solid organ transplant and concomitant use of immunosuppression
- Prior use of cardiopulmonary resuscitation (CPR) in index admission
- Active bleeding
- Heparin allergy if heparin is required for therapeutic apheresis
- Metastatic disease with life expectancy of <12 months and ECOG score of at least 2
- Haematological malignancy if not in remission
- Dialysis dependent Chronic Kidney Disease (CKD Stage 5-D)
- Known allergy to components of NucleoCapture
- Presence of severe multiple organ failure at the point of enrolment as evidenced by:; Severe refractory vasoplegic failure; Norepinephrine dose > 0.60 μg/kg/min; Use of epinephrine; Concomitant cardiogenic shock, clinically suspected or CI<2.2 if measured; Use of dobutamine, epinephrine, phosphodiesterase inhibitors or levosimendan; Coagulopathy as defined by platelet count <50
- Expected duration of invasive mechanical ventilation less than 48 hours
- Calculated Plasma Volume greater than 5000ml as determined by an estimation of total blood volume (according to Nadler's formula, incorporating height, weight and sex) multiplied by (1- Haematocrit). A total blood volume calculator is available at https://www.omnicalculator.com/health/blood-volume
- Liver cirrhosis (histologically proven or clinically suspected)
- Citrate intolerance if citrate is required for therapeutic apheresis
- Requirement for extracorporeal membrane oxygenation (ECMO)
- Patient expected to die within 48 hours of admission to ICU
- Current Participation in another interventional clinical trial
- Pregnancy (as established by the presence of beta human chorionic gonadotropin in urine or blood)
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a prospective, multinational, multicentre, randomised, parallel-group, open-label study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)/Neutrophil Extracellular Traps (NETs) in sepsis patients.
The 2 groups in the trial
- NucleoCapture TreatmentTreatment being tested
Participants in the NucleoCapture treatment arm will receive Standard of Care plus three treatment sessions with the NucleoCapture treatment device. The device consists of 100ml NucleoCapture selective adsorber.
Treatment: NucleoCapture device
- Standard of CareNo study treatment, for comparison
Participants in the Standard of Care arm will receive standard medical care alone.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis
- Criteria questions
- Built from NCT05647096, who can take part
- Record updated
- 29 November 2024